Diabetes Mellitus, Type 2  >>  taspoglutide (BIM51077)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

10 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
taspoglutide (BIM51077) / Ipsen
NCT00809705 / 2008-003575-47: A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes

Completed
3
60
Europe
Placebo, taspoglutide
Hoffmann-La Roche
Diabetes Mellitus Type 2
10/09
10/09
NCT00744926 / 2008-001765-28: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.

Checkmark P3 data
Feb 2012 - Feb 2012: P3 data
Completed
3
373
US, Europe, RoW
placebo, taspoglutide
Hoffmann-La Roche
Diabetes Mellitus Type 2
04/10
04/10
NCT00823992 / 2008-005809-20: A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy

Checkmark
Feb 2013 - Feb 2013: 
Completed
3
305
US, Canada, Europe, RoW
placebo, taspoglutide
Hoffmann-La Roche
Diabetes Mellitus Type 2
05/10
05/10
NCT00744367 / 2008-001744-39: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.

Checkmark P3 data
Apr 2012 - Apr 2012: P3 data
Checkmark P3 data
Apr 2012 - Apr 2012: P3 data
Completed
3
326
US, Canada, Europe, RoW
metformin, pioglitazone, placebo, taspoglutide
Hoffmann-La Roche
Diabetes Mellitus Type 2
11/10
11/10
NCT00909597 / 2009-009157-24: A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes

Completed
3
756
US, Canada, Europe, RoW
pioglitazone, taspoglutide
Hoffmann-La Roche
Diabetes Mellitus Type 2
11/10
11/10
NCT00755287 / 2008-001855-23: A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.

Checkmark P3 data
Sep 2012 - Sep 2012: P3 data
Checkmark Data
Sep 2010 - Sep 2010: Data
Completed
3
1072
US, Canada, Europe, RoW
insulin glargine, metformin, taspoglutide
Hoffmann-La Roche
Diabetes Mellitus Type 2
12/10
12/10
NCT01051011: A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy

Terminated
3
370
RoW
insulin glargine, metformin, taspoglutide
Hoffmann-La Roche
Diabetes Mellitus Type 2
12/10
12/10
NCT01018173 / 2009-014986-22: A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease

Completed
3
2118
US, Canada, Europe, RoW
placebo, taspoglutide
Hoffmann-La Roche
Diabetes Mellitus Type 2
01/11
01/11
NCT00717457 / 2008-001856-36: A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

Checkmark
Aug 2013 - Aug 2013: 
Checkmark P3 data
Nov 2012 - Nov 2012: P3 data
Checkmark Data
More
Completed
3
1189
US, Canada, Europe, RoW
exenatide, taspoglutide
Hoffmann-La Roche
Diabetes Mellitus Type 2
03/11
03/11
NCT00754988 / 2008-001854-42: A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.

Checkmark P3 data
Nov 2012 - Nov 2012: P3 data
Checkmark Data
Sep 2010 - Sep 2010: Data
Completed
3
666
US, Canada, Europe, RoW
Metformin, Placebo (matching sitagliptin), Placebo (matching taspoglutide), Sitagliptin, Taspoglutide
Hoffmann-La Roche
Diabetes Mellitus Type 2
03/11
03/11

Download Options